We performed retrospective analysis of relapsed/refractory multiple myeloma (RRMM) patients previously exposed to daratumumab treated with ixazomib, lenalidomide, dexamethasone (IRd) regimen in real clinical practice. Our aim was to evaluate efficacy of IRd in these patients and select a subset of patients that would benefit from this treatment the most. In total, we analyzed 43 daratumumab-exposed RRMM patients treated in our center. Minimal response or better was achieved by 53.5% of patients from the cohort. Median progression free survival (PFS) was 4.56 months (95% CI: 2.56, 8.03) and median overall survival (OS) was 28.92 months (95% CI: 5.4, NR). Duration of response (DOR) was evaluable in 28 patients and reached a median of 21.3 months (95% CI: 6.85, NR). Next, we evaluated hazard ratios (HR) for OS and PFS. There was improved OS in patients that were not-triple refractory or worse (HR = 0.39, 95%Cl (0.14; 1.10), p = .07) and in patients, that had less than three previous lines of treatment (LOT) (HR = 0.13, 95%Cl (0.03; 0.6) p = .003). Similar to OS, there was improved PFS in patients, that were not triple-refractory or worse (HR = 0.52, 95%Cl (0.25; 1.10), p = .08). We concluded, that the best survival benefit for RRMM patients pretreated with daratumumab to IRd regimen was observed in patients that were not triple-refractory and had less than three previous lines of treatment (LOT). The DOR in these patients was 21.3 months (95% CI: 6.85, NR).

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Medical Genetics and Genomics Faculty of Medicine Masaryk University and University Hospital Brno Brno Czech Republic

See more in PubMed

Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086‐1107. doi:10.1002/ajh.26590

Maluskova D, Svobodova I, Kucerova M, et al. Epidemiology of Multiple Myeloma in The Czech Republic. Epidemiologie mnohočetného myelomu v České republice. Klin Onkol. 2017;30(Supplementum2):35‐42. doi:10.14735/amko20172S35

Thorsteinsdottir S, Dickman PW, Landgren O, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population‐based study. Haematologica. 2018;103(9):e412‐e415. doi:10.3324/haematol.2017.183475

Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the international staging system (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23(6):1152‐1157. doi:10.1038/leu.2008.402

Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516‐2520. doi:10.1182/blood‐2007‐10‐116129

Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104‐2115. doi:10.1056/NEJMoa1817249

Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691‐4695. doi:10.1182/blood‐2010‐10‐299487

Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38‐targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266‐2275. doi:10.1038/s41375‐019‐0435‐7

Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21(1):606. doi:10.1186/s12885‐021‐08280‐y

Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621‐1634. doi:10.1056/NEJMoa1516282

Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328‐e346. doi:10.1016/S1470‐2045(16)30206‐6

Wang PF, Yee CW, Gorsh B, et al. Treatment patterns and overall survival of patients with double‐class and triple‐class refractory multiple myeloma: a US electronic health record database study. Leuk Lymphoma. 2023;64(2):398‐406. doi:10.1080/10428194.2022.2140284

Groen K, van de Donk N, Stege C, Zweegman S, Nijhof IS. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019;11:2663‐2675. doi:10.2147/CMAR.S150653

Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT‐3 Trial. J Clin Oncol. 2023;41(3):568‐578. doi:10.1200/JCO.21.02815

Sammartano V, Franceschini M, Fredducci S, et al. Anti‐BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023;6(1):169‐181. doi:10.20517/cdr.2022.138

Sidiqi MH, Al Saleh AS, Kumar SK, et al. Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials. Am J Hematol. 2021;96(9):1131‐1136. doi:10.1002/ajh.26269

Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non‐interventional, multinational study of real‐life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371‐1376. doi:10.1038/s41375‐022‐01531‐2

Huang H, Wu HW, Hu YX. Current advances in chimeric antigen receptor T‐cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ Sci B. 2020;21(1):29‐41. doi:10.1631/jzus.B1900351

Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, Pour L, Pavlicek P, Mistrik M, Brozova L, Krhovska P, Machalkova K, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Capkova L, Sykora M, Kessler P, Stejskal L, Heindorfer A, Ullrychova J, Skacel T, Maisnar V, Hajek R. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer 2021;21(1):73. doi: 10.1186/s12885‐020‐07732‐1

Hajek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low‐dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31(1):107‐114. doi:10.1038/leu.2016.176

Usmani S, Ahmadi T, Ng Y, et al. Analysis of real‐world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355‐1361. doi:10.1634/theoncologist.2016‐0104

Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017;178(4):571‐582. doi:10.1111/bjh.14733

Costa LJ, Lin Y, Cornell RF, et al. Comparison of Cilta‐cel, an anti‐BCMA CAR‐T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(5):326‐335. doi:10.1016/j.clml.2021.10.013